TSRO - Tesaro, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Tesaro, Inc.

1000 Winter Street
Waltham, MA 02451
United States
339-970-0900
http://www.tesarobio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees715

Key Executives

NameTitlePayExercisedYear Born
Mr. Leon O. Moulder Jr.Co-Founder, CEO & Director1.09MN/A1957
Dr. Mary Lynne HedleyCo-Founder, Pres, COO & Director1.01MN/A1963
Mr. Timothy R. PearsonExec. VP & CFO646.76kN/A1968
Dr. Jeffrey H. Hanke Ph.D.Chief Scientific Officer and Exec. VP of R&D703.97k862.44k1957
Dr. Martin H. Huber Jr.Sr. VP & Chief Medical Officer732.52kN/A1960
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Tesaro, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.